163 related articles for article (PubMed ID: 26232305)
1. Development of an ELISA-Based HDAC Activity Assay for Characterization of Isoform-Selective Inhibitors.
Padige G; Negmeldin AT; Pflum MK
J Biomol Screen; 2015 Dec; 20(10):1277-85. PubMed ID: 26232305
[TBL] [Abstract][Full Text] [Related]
2. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
[TBL] [Abstract][Full Text] [Related]
3. Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy.
Ganai SA
Curr Top Med Chem; 2016; 16(22):2441-52. PubMed ID: 26873193
[TBL] [Abstract][Full Text] [Related]
4. Cell-based multi-substrate assay coupled to UHPLC-ESI-MS/MS for a quick identification of class-specific HDAC inhibitors.
Zwick V; Simões-Pires C; Cuendet M
J Enzyme Inhib Med Chem; 2016; 31(sup1):209-214. PubMed ID: 27149362
[TBL] [Abstract][Full Text] [Related]
5. Inside HDAC with HDAC inhibitors.
Bertrand P
Eur J Med Chem; 2010 Jun; 45(6):2095-116. PubMed ID: 20223566
[TBL] [Abstract][Full Text] [Related]
6. Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay.
Uba AI; Yelekçi K
J Biomol Struct Dyn; 2018 Sep; 36(12):3231-3245. PubMed ID: 28938863
[TBL] [Abstract][Full Text] [Related]
7. Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next.
Thaler F; Mercurio C
ChemMedChem; 2014 Mar; 9(3):523-6. PubMed ID: 24730063
[TBL] [Abstract][Full Text] [Related]
8. Explorative study on isoform-selective histone deacetylase inhibitors.
Suzuki T
Chem Pharm Bull (Tokyo); 2009 Sep; 57(9):897-906. PubMed ID: 19721249
[TBL] [Abstract][Full Text] [Related]
9. Chemical origins of isoform selectivity in histone deacetylase inhibitors.
Butler KV; Kozikowski AP
Curr Pharm Des; 2008; 14(6):505-28. PubMed ID: 18336297
[TBL] [Abstract][Full Text] [Related]
10. Development and therapeutic impact of HDAC6-selective inhibitors.
Dallavalle S; Pisano C; Zunino F
Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920
[TBL] [Abstract][Full Text] [Related]
11. Isoform-selective histone deacetylase inhibitors.
Itoh Y; Suzuki T; Miyata N
Curr Pharm Des; 2008; 14(6):529-44. PubMed ID: 18336298
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of novel FK228 analogues as potential isoform selective HDAC inhibitors.
Narita K; Matsuhara K; Itoh J; Akiyama Y; Dan S; Yamori T; Ito A; Yoshida M; Katoh T
Eur J Med Chem; 2016 Oct; 121():592-609. PubMed ID: 27318982
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for the design and synthesis of selective HDAC inhibitors.
Di Micco S; Chini MG; Terracciano S; Bruno I; Riccio R; Bifulco G
Bioorg Med Chem; 2013 Jul; 21(13):3795-807. PubMed ID: 23693069
[TBL] [Abstract][Full Text] [Related]
14. Towards isozyme-selective HDAC inhibitors for interrogating disease.
Gupta P; Reid RC; Iyer A; Sweet MJ; Fairlie DP
Curr Top Med Chem; 2012; 12(14):1479-99. PubMed ID: 22827519
[TBL] [Abstract][Full Text] [Related]
15. False HDAC Inhibition by Aurone Compound.
Itoh Y; Suzuki M; Matsui T; Ota Y; Hui Z; Tsubaki K; Suzuki T
Chem Pharm Bull (Tokyo); 2016; 64(8):1124-8. PubMed ID: 27477650
[TBL] [Abstract][Full Text] [Related]
16. Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic alpha3beta-tetrapeptides.
Olsen CA; Ghadiri MR
J Med Chem; 2009 Dec; 52(23):7836-46. PubMed ID: 19705846
[TBL] [Abstract][Full Text] [Related]
17. Targeting class I histone deacetylases in cancer therapy.
Delcuve GP; Khan DH; Davie JR
Expert Opin Ther Targets; 2013 Jan; 17(1):29-41. PubMed ID: 23062071
[TBL] [Abstract][Full Text] [Related]
18. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
Weichert W; Röske A; Niesporek S; Noske A; Buckendahl AC; Dietel M; Gekeler V; Boehm M; Beckers T; Denkert C
Clin Cancer Res; 2008 Mar; 14(6):1669-77. PubMed ID: 18347167
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylases: structural determinants of inhibitor selectivity.
Micelli C; Rastelli G
Drug Discov Today; 2015 Jun; 20(6):718-35. PubMed ID: 25687212
[TBL] [Abstract][Full Text] [Related]
20. A homogeneous cellular histone deacetylase assay suitable for compound profiling and robotic screening.
Ciossek T; Julius H; Wieland H; Maier T; Beckers T
Anal Biochem; 2008 Jan; 372(1):72-81. PubMed ID: 17868634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
